Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. FDA. FDA approves new, targeted treatment for bladder cancer [media release]. 6 Jun 2016. http://www.fda.gov .
2. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7.
3. Genentech Inc. Prescribing information for Tecentriq™ (atezolizumab) injection, for intravenous use. 2016. http://www.gene.com/download/pdf/tecentriq_prescribing.pdf . Accessed 20 May 2016.
4. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20.
5. Petrylak DP, Powles T, Bellmunt J, et al. A phase Ia study of MPDL3280A (anti-PDL1): updated response and survival data in urothelial bladder cancer (UBC) [abstract no. 4501]. J Clin Oncol. 2015;33(Suppl).
Cited by
103 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献